The United States has been witness to a dramatic decline in mortality from prostate cancer over the past three decades. Although there is a lot of speculation as to why this is the case, a major factor appears to be the use of PSA in prostate cancer screening. Especially supporting this concept is the fact that countries that have not implemented PSA based screening have not witnessed a similar decline.
Prostate cancer is the most common cancer in men and the second-leading cause of cancer-related death in men following lung cancer. The risk of prostate cancer is fairly negligible below the age of 40 and still fairly low until age 50. Some medical societies have recommended screening men at increased risk for prostate cancer at age 40 and then to begin routine screening at age 50 or 55.